Open studies conducted by NIDDK Principal Investigators appear below. Study statuses may include the following:
Open: Recruiting - Currently recruiting participants and open to everyone who meets eligibility criteria.
Open: Active, Not Recruiting - Participants are receiving an intervention or being examined, however new participants
are not being recruited or enrolled.
Open: Enrolling by Invitation - People in a particular population were selected in advance and invited to participate.
The study is not open to everyone who meets the eligibility criteria.
Open: Available for Expanded Access - Patients who are not participants in the clinical study may be able to
gain access to the drug, biologic, or medical device being studied.
Studies Seeking Patients
The purpose of this study is to find substances in the blood and urine that indicate that a
person has kidney damage. It will identify proteins found only in patients with acute kidney
failure but not in normal healthy people or in patients with volume depletion.
Adults and children who are at least 3 years old who fall into one of the following four
categories may be eligible for this study:
1. Are healthy and have normal kidney function
2. Have volume depletion (this condition differs from acute kidney failure in that it is
easily treated with fluids)
3. Are at high risk of kidney failure
4. Have acute kidney failure (kidney shutdown)
All study participants will have a history and physical examination. Up to four blood samples
of 3 tablespoons each will be taken for laboratory analysis. Urine will be collected for
analysis and to measure urine output. The participants length of stay in the study varies.
People with normal kidney function will be in the study for 1 day and patients with volume
depletion will be studied 3 days. The length of hospitalization of patients at high risk of
kidney failure or in acute kidney failure will depend on the patient s condition and
The results of this study may lead to the development of earlier and more accurate methods
for diagnosing acute kidney failure. With earlier detection, treatment could be started
earlier, possibly preventing further damage and helping recovery of injury that has already
The trial is Open with a status of Active, not recruiting.
Robert A Star, M.D.